Next Article in Journal
From Basic Research to Clinical Practice: Considerations for Treatment Drugs for Silicosis
Previous Article in Journal
UV-A Radiation: Safe Human Exposure and Antibacterial Activity
Previous Article in Special Issue
Hericium erinaceus Promotes Anti-Inflammatory Effects and Regulation of Metabolites in an Animal Model of Cerebellar Ataxia
 
 
Article
Peer-Review Record

Genetically Engineered Artificial Microvesicles Carrying Nerve Growth Factor Restrains the Progression of Autoimmune Encephalomyelitis in an Experimental Mouse Model

Int. J. Mol. Sci. 2023, 24(9), 8332; https://doi.org/10.3390/ijms24098332
by Reem Alatrash 1, Maria Golubenko 1, Ekaterina Martynova 1, Ekaterina Garanina 1, Yana Mukhamedshina 1,2, Svetlana Khaiboullina 1, Albert Rizvanov 1, Ilnur Salafutdinov 1,2,* and Svetlana Arkhipova 1,2
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Int. J. Mol. Sci. 2023, 24(9), 8332; https://doi.org/10.3390/ijms24098332
Submission received: 17 April 2023 / Revised: 27 April 2023 / Accepted: 2 May 2023 / Published: 5 May 2023
(This article belongs to the Special Issue Molecular Research in Neuroimmunological Disorders)

Round 1

Reviewer 1 Report

The paper explores a potential new therapy for multiple sclerosis (MS). The therapy involves the use of adipose mesenchymal stem cells (ADMSCs) derived, cytochalasin B induced artificial microvesicles (MVs) expressing nerve growth factor (NGF) on a EAE model of MS. The study found that the injection of ADMSCs-MVs-NGF led to a significant decrease in neurogliosis post EAE induction and stimulated axon regeneration. Therefore, the paper concludes that artificial ADMSCs-MVs-NGF could be a new effective treatment for MS, modulating gliosis in the EAE model.

This manuscript is well-written, easy to follow, and clearly provides the authors’ view on this subject. I am confident that the manuscript will be well-received by the readers of IJMS.

 

Author Response

Esteemed Reviewer, we express our sincere gratitude for your careful review and consideration of our manuscript.

Reviewer 2 Report

The authors have developed ADMSCs derived, cytochalasin B induced artificial MVs , which expressing NGF (ADMSCs-MVs-NGF). 

The characterization analysis showed that confirmation NGF expression of ADMSCs-MVs-NGF. 

The therapeutic efficacy of ADMSCs-MVs-NGF was investigated in a mouse model of multiple sclerosis experimental auto-immune encephalomyelitis (EAE).

The injection of ADMSCs-MVs-NGF into EAE mice showed a significant decrease in neurogliosis.  

Comments

1) The authors may include the scale of symptoms  of EAE as a graph. 

2) Was cytokine profile evaluated on 21 p.i.? Please indicate the day of serum was collected. 

Comments for author File: Comments.pdf


Author Response

Dear Reviewer: 
Thank you very much for having considered our manuscript. We are very happy to have received a positive evaluation, and we would like to express our appreciation to you. We added recommended changes in the current paper.  

Back to TopTop